Retrospective analysis of the safety of peripherally inserted catheters versus implanted port catheters during first-line treatment for patients with diffuse large B-cell lymphoma.
central venous catheter
diffuse large B-cell lymphoma
thrombosis
Journal
European journal of haematology
ISSN: 1600-0609
Titre abrégé: Eur J Haematol
Pays: England
ID NLM: 8703985
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
revised:
07
03
2022
received:
28
12
2021
accepted:
09
03
2022
pubmed:
15
3
2022
medline:
15
6
2022
entrez:
14
3
2022
Statut:
ppublish
Résumé
Both peripherally inserted central catheters (PICCs) and implanted port catheters (PORTs) are commonly used for the delivery of immunochemotherapy. We compared the safety of the two types of devices in a homogeneous and monocentric population of diffuse large B-cell lymphoma (DLBCL) patients who were treated with first-line immunochemotherapy by evaluating the numbers of catheter-related venous thromboses (VTs) and infections that occurred in the six months after implantation according to the type of device. Using a propensity score, the adjusted relative risk (ARR) between the type of catheter and the occurrence of catheter-related complications (infection and/or VT) of interest was retrospectively determined. 479 patients were enrolled (266 PORTs/213 PICCs), and 26 VTs (5.4%) and 30 infections (6.3%) were identified in the period following PICC/PORT implantation. The adjusted relative risk (ARR) of catheter-related complications (infection and/or VT) according to the type of device was 2.6 (95% CI =1.3-5.9, p = .0075). This risk increase associated with the PICC device was significant for both infections (ARR = 3.2; 95% CI = 1.3-10.9) and thrombosis (ARR = 4; 95% CI = 1.5-11.6). Our study supports the preferential use of PORTs for the first line of treatment for DLBCL patients.
Identifiants
pubmed: 35285085
doi: 10.1111/ejh.13767
pmc: PMC9313835
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
41-49Informations de copyright
© 2022 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.
Références
Cancer Nurs. 2020 Nov/Dec;43(6):455-467
pubmed: 31464692
Lancet. 2013 Jul 27;382(9889):311-25
pubmed: 23697825
J Clin Oncol. 2013 Apr 1;31(10):1357-70
pubmed: 23460705
Br J Anaesth. 2019 Jun;122(6):734-741
pubmed: 31005243
Support Care Cancer. 2014 Jan;22(1):121-8
pubmed: 24005884
BMJ Open. 2021 Jul 5;11(7):e045895
pubmed: 34226216
Pediatr Blood Cancer. 2007 Jan;48(1):35-8
pubmed: 16358302
Multivariate Behav Res. 2011 May;46(3):399-424
pubmed: 21818162
Ann Intern Med. 2015 Sep 15;163(6 Suppl):S1-40
pubmed: 26369828
Stat Med. 2021 Mar 30;40(7):1718-1735
pubmed: 33377193
Am J Hematol. 2017 Dec;92(12):E656-E659
pubmed: 28891226
Bone Marrow Transplant. 2005 Feb;35(4):397-401
pubmed: 15640824
Clin Microbiol Infect. 2002 May;8(5):265-74
pubmed: 12047403
Br J Haematol. 2005 Jun;129(6):811-7
pubmed: 15953009
Eur J Cancer. 2020 Feb;126:116-124
pubmed: 31931269
Eur J Haematol. 2022 Jul;109(1):41-49
pubmed: 35285085
J Clin Oncol. 2005 Nov 1;23(31):7864-70
pubmed: 16258088
Acta Anaesthesiol Scand. 2020 Mar;64(3):385-393
pubmed: 31721153
Thromb Res. 2014 May;133 Suppl 2:S23-8
pubmed: 24862141
Anaesthesia. 2012 Jan;67(1):65-71
pubmed: 21972789
Acta Oncol. 2013 Jun;52(5):886-92
pubmed: 23472835
Lancet. 2021 Jul 31;398(10298):403-415
pubmed: 34297997
Med Oncol. 2017 Dec 4;35(1):5
pubmed: 29209847
J Vasc Access. 2020 Jan;21(1):45-54
pubmed: 31177939
J Thromb Haemost. 2017 Oct;15(10):1951-1962
pubmed: 28796444
Leuk Lymphoma. 2006 Jun;47(6):1029-33
pubmed: 16840193
Oncotarget. 2016 Jun 7;7(23):35404-11
pubmed: 27078849
Am J Hematol. 2016 Oct;91(10):1014-9
pubmed: 27380861
N Engl J Med. 2021 Mar 4;384(9):842-858
pubmed: 33657296
Blood Rev. 2018 Mar;32(2):144-158
pubmed: 29126566